Memorial Sloan Kettering Cancer Center
Industry
- Academic and Research Institutions
Latest on Memorial Sloan Kettering Cancer Center
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
Ajax Therapeutics, Inc. is going after an old target in myelofibrosis and other myeloproliferative neoplasms (MPNs) in a new way with its type II JAK2 inhibitor, AJ1-11095, which it will take into th
Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only
March has been a big month for venture capital mega-rounds of $100m or more and Flare Therapeutics Inc. continued the trend, announcing 22 March that it completed a $123m series B round to fund disc